Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.
Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. Strober B, et al. Among authors: cather j. J Am Acad Dermatol. 2009 Jul;61(1 Suppl 1):S1-S46. doi: 10.1016/j.jaad.2009.03.017. J Am Acad Dermatol. 2009. PMID: 19527820
Novel therapies for psoriasis.
Cather J, Menter A. Cather J, et al. Am J Clin Dermatol. 2002;3(3):159-73. doi: 10.2165/00128071-200203030-00003. Am J Clin Dermatol. 2002. PMID: 11978137 Review.
Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Crowley JJ, Warren RB, Cather JC. Crowley JJ, et al. Among authors: cather jc. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1676-1684. doi: 10.1111/jdv.15653. Epub 2019 Jun 27. J Eur Acad Dermatol Venereol. 2019. PMID: 31054215 Free PMC article. Review.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group. Ryan C, et al. Among authors: cather jc. Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22. Br J Dermatol. 2018. PMID: 29747232 Clinical Trial.
Changing paradigms in dermatology: nuclear hormone receptors.
Winterfield L, Cather J, Cather J, Menter A. Winterfield L, et al. Among authors: cather j. Clin Dermatol. 2003 Sep-Oct;21(5):447-54. doi: 10.1016/j.clindermatol.2003.08.011. Clin Dermatol. 2003. PMID: 14678724 Review.
Cyclosporine and tacrolimus in dermatology.
Cather JC, Abramovits W, Menter A. Cather JC, et al. Dermatol Clin. 2001 Jan;19(1):119-37, ix. doi: 10.1016/s0733-8635(05)70234-5. Dermatol Clin. 2001. PMID: 11155577 Review.
97 results